Compare NFE & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NFE | XOMA |
|---|---|---|
| Founded | 2014 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 308.6M |
| IPO Year | 2018 | N/A |
| Metric | NFE | XOMA |
|---|---|---|
| Price | $1.07 | $27.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $7.70 | ★ $60.60 |
| AVG Volume (30 Days) | ★ 5.5M | 134.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,364,860,000.00 | N/A |
| Revenue This Year | N/A | $76.93 |
| Revenue Next Year | $79.17 | $29.28 |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.98 | $18.40 |
| 52 Week High | $12.59 | $39.92 |
| Indicator | NFE | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 41.38 | 56.49 |
| Support Level | $1.03 | $23.92 |
| Resistance Level | $1.40 | $27.68 |
| Average True Range (ATR) | 0.09 | 1.51 |
| MACD | -0.00 | 0.25 |
| Stochastic Oscillator | 8.57 | 78.63 |
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.